TANDEM DIABETES CARE INC
About TANDEM DIABETES CARE INC
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0B
- Net income
- -$204.7M
- Total assets
- $881.1M
- Market cap
- $1.3B
- Gross margin
- 53.8%
- Operating margin
- -18.5%
- Net margin
- -20.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.0B
- Cost of revenue
- $468.7M
- Gross profit
- $546.0M
- Operating expenses
- $733.3M
- Operating income
- -$187.3M
- Income tax
- $4.4M
- Net income
- -$204.7M
- EPS (basic)
- $-3.04
- EPS (diluted)
- $-3.04
Balance sheet
- Total assets
- $881.1M
- Current assets
- $618.1M
- Total liabilities
- $725.9M
- Current liabilities
- $242.7M
- Shareholders’ equity
- $155.2M
Cash flow
- Operating cash flow
- -$9.7M
- Investing cash flow
- $72.9M
- Financing cash flow
- -$43.4M
- Net cash flow
- $21.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-3.04
- Shares outstanding
- 71.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 14, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $204.7M in FY2025.
- Revenue grew 44% from FY2021 to FY2025.
- Gross margin of 53.8%, net margin -20.2%.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TANDEM DIABETES CARE INC.
Write a review
News about TANDEM DIABETES CARE INC
News & sentiment via Polygon.io
